Longitudinal Relationship Between Retinal Diabetic Neurodegeneration and Progression of Diabetic Retinopathy in Patients With Type 2 Diabetes
Overview
Authors
Affiliations
Purpose: To investigate the longitudinal relationship between diabetic retinal neurodegeneration and the progression of diabetic retinopathy (DR) by measuring macular ganglion cell-inner plexiform layer (mGCIPL) thickness in patients with type 2 diabetes (T2DM).
Design: Retrospective cohort study.
Methods: T2DM patients with no DR or mild nonproliferative DR (NPDR) followed up for ≥4 years were included in this study. DR was graded according to retinal photography, and mean parafoveal mGCIPL thickness was measured using optical coherence tomography with at least a 6-month interval from baseline. Hazard ratios (HR) for predicting 2-step progression and development of proliferative DR (PDR) were calculated using Cox proportional hazard modeling using baseline clinical factors.
Results: Of 87 eyes of T2DM patients, 39 (44.8%) exhibited 2-step DR progression and 6 (6.9%) experienced progression to PDR. Patients with DR progression exhibited longer T2DM duration, thinner mGCIPL, greater mGCIPL thinning rate, severe cardiac autonomic neuropathy (CAN), lower peripheral nerve-conduction velocity, and higher glycated hemoglobin A1c level. Multivariate regression modeling revealed that baseline mGCIPL thickness (HR = 0.94), mGCIPL thinning rate (HR = 1.924), CAN score (HR = 1.248), and conduction velocity of peripheral nerves (HR = 0.894) were significant predictive factors for DR progression (area under the curve = 0.92).
Conclusion: Progressive loss of mGCIPL is an independent risk factor for progression in early-stage DR. Further assessment of autonomic and peripheral nerve functions can increase sensitivity in predicting aggravation of DR in patients with T2DM.
Tang Z, Yang D, Nguyen T, Zhang S, Fang D, Chan V Invest Ophthalmol Vis Sci. 2025; 66(2):32.
PMID: 39932471 PMC: 11817850. DOI: 10.1167/iovs.66.2.32.
Gonmori M, Machida S, Inoue S, Ebihara S, Misu K Jpn J Ophthalmol. 2025; 69(1):49-58.
PMID: 39883242 DOI: 10.1007/s10384-024-01154-3.
Lai C, Su T, Cao J, Li Q, Du Z, Wang Y Invest Ophthalmol Vis Sci. 2024; 65(14):20.
PMID: 39656471 PMC: 11636663. DOI: 10.1167/iovs.65.14.20.
Jia J, Liu B, Wang X, Ji F, Wen F, Xu H Front Microbiol. 2024; 15:1453436.
PMID: 39220039 PMC: 11362098. DOI: 10.3389/fmicb.2024.1453436.
Cell and molecular targeted therapies for diabetic retinopathy.
Reddy S, Devi V, Seetharaman A, Shailaja S, Bhat K, Gangaraju R Front Endocrinol (Lausanne). 2024; 15:1416668.
PMID: 38948520 PMC: 11211264. DOI: 10.3389/fendo.2024.1416668.